Jefferies Downgrades Dr. Reddy's Laboratories (RDY) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Dr. Reddy’s Q1 FY17 Financial Results
July 26, 2016 2:03 PM EDTHYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY):
Revenues at Rs. 32.3 billion
  Â(YoY decline of 14%)
ÂEBITDA at Rs. 4.0 billion
(12.3% of the revenues)
 ... More